Event context and recent performance

Amgen (AMGN) has been in focus after recent trading, with the stock last closing at US$355.20. Over the past month it gained about 5.6%, while the past 3 months show a decline of roughly 3.0%.

That recent 5.6% 1 month share price return sits against an 8.4% year to date share price gain, while the 1 year total shareholder return of 23.9% points to momentum that has been building over a longer stretch.

If Amgen has you thinking about where else capital could work hard in healthcare, this is a good moment to scan 40 healthcare AI stocks

With Amgen trading slightly above the average analyst price target yet showing a large modelled intrinsic discount, the key question is whether the stock is still undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 0.8% Overvalued

Compared with the last close at $355.20, the most widely followed fair value estimate of about $352 per share points to only a small valuation gap, so the real interest sits in what is driving that number.

Advancements in personalized and targeted therapies, reflected in the robust late-stage pipeline (e.g., MariTide for obesity/type 2 diabetes, Repatha and olpasiran for cardiovascular, multiple bispecific T-cell engagers for oncology), position Amgen to launch high-margin, first-in-class products that drive both top-line growth and margin expansion in the coming years.

Want to see what this pipeline optimism actually assumes? Revenue growth steps up, margins reset higher, and future earnings power leans on a richer valuation multiple. The detail behind that trade off sits inside the narrative.

Result: Fair Value of $352 (OVERVALUED)

However, there are still pressure points to watch, including drug pricing reform and biosimilar competition around key products that could challenge those growth and margin assumptions.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Cash Flows Tell a Different Story

The earlier fair value of about $352 per share, based on analyst earnings and multiples, presents Amgen as roughly fairly priced. Our DCF model takes a different angle and values the stock at about $664 per share, which implies it is trading at a sizeable discount.

This gap, between a 0.8% premium to the analyst fair value and a 46.5% discount to the DCF fair value, raises a practical question for you as an investor: which set of assumptions about future cash flows feels closer to reality?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Amgen for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment split between potential upside and real concerns, this is the kind of setup where acting quickly to form your own view really matters. Take a closer look at the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that might fit your style even better. Put the screener to work and let it surface ideas for you.

• Target potential upside with companies that combine quality and attractive pricing by scanning the 44 high quality undervalued stocks.
• Strengthen your income potential by focusing on reliable payers in the 8 dividend fortresses.
• Dial back risk by filtering for steadier businesses through the 71 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.